AUA 2024 VL

Innovative Trials Highlight Progress in Treating Urothelial Carcinoma at AUA 2024 - Karim Chamie

Details
Sam Chang interviews Karim Chamie about pivotal clinical trials in urothelial carcinoma presented at AUA 2024. Dr. Chamie discusses the MoonRISe-1 trial, a Phase III study on TAR-210 (an erdafitinib intravesical delivery system) for intermediate-risk non-muscle-invasive bladder cancer, highlighting its innovative approach and potential to change the treatment landscape. He also reviews the SunRISe...

SLICE: Revolutionizing Surgical Training with Ultra-Realistic Simulation - Ahmed Ghazi

Details
Zach Klaassen interviews Ahmed Ghazi about his work in robotic simulation. Dr. Ghazi shares his journey from laparoscopic surgery in Europe to robotic surgery in the US, emphasizing the need for realistic surgical training tools. He developed 3D-printed, hydrogel organs that simulate bleeding, enhancing training realism. At Hopkins, Dr. Ghazi established SLICE (Surgical Learning and Innovation Cen...

KEYNOTE-676 Cohort A: Pembrolizumab + BCG for Previously BCG-Treated NMIBC - Neal Shore

Details
Sam Chang interviews Neal Shore about the KEYNOTE-676 trial. This global study evaluates the efficacy of combining Pembrolizumab with BCG induction and maintenance in patients who had previously received an induction course of BCG without maintenance. Dr. Shore discusses the study’s aim to enhance the effectiveness of BCG therapy in non-muscle invasive bladder cancer (NMIBC) by adding a checkpoint...

AUA 2024 Urothelial Carcinoma Highlights - Woodson Smelser

Details
Sam Chang interviews Woodson Smelser to discuss takeaways from the AUA Annual Meeting in urothelial carcinoma, highlighting the rapid advancements in non-muscle invasive bladder cancer therapies. He emphasizes the importance of new FDA-approved agents like Pembrolizumab, Nadofaragene, and Nogapendekin. Dr. Smelser also reviews clinical trials, such as the TAR-200 device and the CG0070 adenovirus....

Pembrolizumab + Chemoradiation vs. Trimodality Therapy for Muscle-Invasive Bladder Cancer: The KEYNOTE-992 Trial - Neal Shore

Details
Sam Chang interviews Neal Shore about the KEYNOTE-992 trial comparing immunotherapy combined with chemoradiation to standard trimodality therapy for muscle-invasive bladder cancer. Dr. Shore explains that the trial evaluates Pembrolizumab with chemoradiation versus placebo with chemoradiation in patients suitable for bladder-sparing approaches. He emphasizes the importance of offering bladder-pres...

Advancing Urology Priorities Through the AMA House of Delegates - Hans Arora

Details
Ruchika Talwar interviews Hans Arora about his extensive involvement in organized medicine through the AMA and the AUA. Dr. Arora shares his journey from an MD-PhD student to a key figure in medical advocacy, emphasizing the importance of organized medicine in influencing healthcare policy. He explains how the AMA’s policy-making process through the House of Delegates affects all medical specialti...

Introducing the Kidney Stone Collaborative: A New Nonprofit for Kidney Stone Patients - Justin Ziemba

Details
Ruchika Talwar interviews Justin Ziemba about a significant development in kidney stone disease advocacy and research. Dr. Ziemba announces the creation of the Kidney Stone Collaborative (KSC), a new nonprofit organization dedicated to improving research and advocacy for kidney stone patients. He explains that this initiative has been months in the making, involving scientific experts, patient adv...

The EvoPAR-Prostate 01 Trial: Novel PARP Inhibitor Saruparib in mHSPC - Neeraj Agarwal

Details
Zach Klaassen discusses the EvoPAR-Prostate 01 trial with Neeraj Agarwal. The trial examines a new PARP inhibitor combined with ARPI in metastatic hormone-sensitive prostate cancer, both in biomarker-positive and -negative populations. Dr. Agarwal explains the rationale based on preclinical data and previous trials like PROpel and TALAPRO-2, showing efficacy in HRR mutation-positive patients and p...

A Comprehensive Guide to Interstitial Cystitis - Jill Peters-Gee

Details
Diane Newman interviews Jill Peters-Gee about her comprehensive book on interstitial cystitis (IC). Dr. Peters-Gee discusses her motivation for writing the book due to outdated resources and new information from the MAPP Network. She explains the terminology confusion between IC and bladder pain syndromes (BPS) and emphasizes the need for phenotyping to tailor treatments. They discuss the importan...

AUA/SUFU Overactive Bladder Guidelines Emphasize Shared Decision-Making - Ariana Smith

Details
Diane Newman interviews Ariana Smith about the newly released AUA/SUFU Overactive Bladder Guidelines. Dr. Smith, who co-chaired the guidelines, emphasizes the shift from a stepwise therapy approach to a patient-centered menu of treatment options. This new guideline encourages shared decision-making, allowing patients to consider all treatments upfront based on their personal values and goals. It i...